Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2026
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability targeting medicine for secondary progressive multiple sclerosis without relapses
23 June 2026 - The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis without relapses ...
Posted by Michael Wonder on 23 Jun 2026
Laboratoires Pierre Fabre receives European Commission approval for Braftovi (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer
22 June 2026 - Laboratoires Pierre Fabre announced today that the European Commission has approved Braftovi (encorafenib) in combination with cetuximab ...
Posted by Michael Wonder on 23 Jun 2026
US WorldMeds receives full US FDA approval of Tecelra (afamitresgene autoleucel) with an expanded indication, extending the first approved engineered T-cell therapy for a solid tumour to children as young as 12
22 June 2026 - US WorldMeds announced that the US FDA has granted full approval of Tecelra (afamitresgene autoleucel) and ...
Posted by Michael Wonder on 23 Jun 2026
AbbVie announces European Commission approval of Skyrizi (risankizumab) for the treatment of paediatric patients with moderate to severe plaque psoriasis
23 June 2026 - AbbVie today announced that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and ...
Posted by Michael Wonder on 23 Jun 2026
Arrowhead Pharmaceuticals receives marketing authorisation in the European Union for Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome
22 June 2026 - Arrowhead Pharmaceuticals today announced that the European Commission has formally granted marketing authorization for Redemplo (plozasiran), ...
Posted by Michael Wonder on 23 Jun 2026
AbbVie announces European Commission approval of Maviret (glecaprevir/pibrentasvir) for people with acute hepatitis C virus infection
23 June 2026 - AbbVie today announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral therapy for ...
Posted by Michael Wonder on 23 Jun 2026
European Commission approves Trodelvy as a first-line treatment for metastatic triple negative breast cancer patients not candidates for PD-(L)1 inhibitors
23 June 2026 - Gilead Sciences today announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) ...
Posted by Michael Wonder on 23 Jun 2026
Achieve Life Sciences receives complete response letter from FDA for cytisinicline NDA
22 June 2026 - Achieve Life Sciences today announced that it has received a complete response letter from the US FDA ...
Posted by Michael Wonder on 23 Jun 2026
Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
23 June 2026 - Today, Allergan Aesthetics announced Health Canada has approved Boey (trenibotulinumtoxinE) for the temporary improvement in the ...
Posted by Michael Wonder on 19 Jun 2026
Recommendations made by the PBAC – May 2026
19 June 2026 - Recommendations made by the PBAC in May 2026 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 19 Jun 2026
US FDA approves an additional indication for Capvaxive (pneumococcal 21-valent conjugate vaccine) in children and adolescents aged 2 through 17 at increased risk for pneumococcal disease
18 June 2026 - Merck today announced that the US FDA has approved an expanded indication for Capvaxive (pneumococcal 21-valent conjugate ...
Posted by Michael Wonder on 17 Jun 2026
FDA approves first single dose generic treatment for influenza
17 June 2026 - The US FDA today approved the first generic of Xofluza (baloxavir marboxil) tablets, the first single-dose treatment ...
Posted by Michael Wonder on 17 Jun 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections
17 June 2026 - GSK and Spero Therapeutics today announced that the US FDA has approved Utebzi, an oral antibiotic for ...
Posted by Michael Wonder on 17 Jun 2026
FDA broadens access to over the counter naloxone nasal spray for opioid overdose
16 June 2026 - The US FDA today approved another over the counter intranasal naloxone product, Rextovy, a 4 mg naloxone ...
Posted by Michael Wonder on 17 Jun 2026
Health Canada approves Zepbound as the first ever obstructive sleep apnea medication in Canada for adults living with obesity
16 June 2026 - Eli Lilly Canada announced today that Health Canada has approved Zepbound (tirzepatide injection) for the treatment of ...